bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role.
'I've seen firsthand in my practice the need for a noninvasive, accurate and real-time diagnostic for lung cancer. I believe CyPath® Lung is particularly useful in managing indeterminate lung nodules by filling a critical gap in clinical decision-making."
Share
Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved research programs, and served in national leadership roles with the American College of Chest Physicians in the areas of interventional pulmonology, lung cancer, and medical ethics.
'It's a privilege to join bioAffinity at such a pivotal time,' Dr. Downie said. 'I've seen firsthand in my practice the need for a noninvasive, accurate and real-time diagnostic for lung cancer. I believe CyPath® Lung is particularly useful in managing indeterminate lung nodules by filling a critical gap in clinical decision-making. I'm excited by the opportunity to expand access to this innovative technology that can save lives.'
In 2007, Dr. Downie left academia and opened a pulmonology practice in rural East Texas, an underserved area with limited access to healthcare. The lack of pulmonary care is exacerbated by an aging population and rising rates of lung disease, including COPD. Most recently, he was the Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical Center.
Dr. Downie earned his PhD in experimental pathology from the State University of New York at Buffalo (SUNY Buffalo) and his medical degree from Northwestern University. He completed residency and fellowship training at the University of North Carolina at Chapel Hill, and subsequently served on the faculty at SUNY Buffalo and the Brody School of Medicine at East Carolina University.
'Dr. Downie brings a rare blend of clinical excellence, research insight, and innovation in delivery of care,' said Maria Zannes, President and CEO of bioAffinity Technologies. 'His depth of experience in interventional pulmonology and his passion for early cancer detection make him the ideal leader to guide our clinical strategy as we scale CyPath® Lung and expand our diagnostic platform to additional diseases.'
Prior to pursuing his career in medicine, Dr. Downie was an Olympic bronze medalist at the 1976 Summer Olympics in Montreal as part of Great Britain's men's 4×200-meter freestyle relay swim team. He also won silver and bronze medals at the 1975 World Aquatics Championships and was a four-time NCAA All-American swimmer for the University of Michigan.
'It's that same spirit of commitment and discipline that has made Dr. Downie a world-class physician respected by his peers throughout the country,' Ms. Zannes said. 'We are delighted to welcome him to bioAffinity.'
About CyPath® Lung
CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding CyPath® Lung's usefulness in managing indeterminate lung nodules by filling a critical gap in clinical decision-making, expanding access to CyPath® Lung technology to save lives, Dr. Downie's contribution to scaling CyPath® Lung, and expanding the Company's diagnostic platform to additional diseases. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to accelerate the commercial growth of CyPath® Lung, Dr. Downie's ability to help expand access to CyPath® Lung technology and guide the Company's clinical strategy, the Company's ability to advance new diagnostics for additional diseases, and the other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Salmonella outbreak causes egg recall; 79 people sick
(WTVO) — An egg producer based in California is recalling over a million eggs across nine states due to a salmonella outbreak, according to the (FDA). The specific type of eggs recalled was cage-free brown eggs manufactured by the August Egg Company. Those eggs were sold between February 3 and May 15. Select Walmart locations had the tainted eggs for sale, including stores in Illinois. They are also being recalled at Save Mart, FoodMaxx, Lucky, Smart & Final, Food 4 Less, Smart and Final, Safeway, Raleys and Ralphs. from the U.S. Centers for Disease Control and Prevention show that 79 people fell ill and 21 people went to the hospital in seven states. The specific container had a plant code number of P-6562 or CA5330 printed on the package. Salmonella infections can happen 12 to 72 hours after eating food that is contaminated. Symptoms of Diarrhea, fever and abdominal cramps can last from four to seven days, according to the . Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
Food recall: Brown eggs sold at grocery stores across California have salmonella risk
A California company is recalling 1.7 million cartons of brown eggs — sold at stores including Walmart in nine states including California — because the eggs may be contaminated with salmonella bacteria. August Egg Company of Hilmar is recalling 1,700,000 dozen brown cage-free and brown certified organic eggs for potential salmonella risk. The eggs were distributed over the last four months, some with sell by dates as late as June 19, according to the recall notice from the Food and Drug Administration. The eggs are linked to an ongoing Salmonella Enteritidis outbreak in seven states, in which 79 people have been sickened and at least 21 hospitalized, but no deaths have been reported, according to the Centers for Disease Control and Prevention. Most of the people sickened (63) live in California, according to the CDC. Nevada and Washington reported four illnesses each, with additional cases in Arizona (3), New Jersey (2), Nebraska (2), Kentucky (1). Ill people in Kentucky, New Jersey, and Washington reported traveling to California and Nevada before they got sick. Most of those sickened (90%) reported eating eggs, the CDC said. Some samples taken by the FDA during an inspection at August Egg Company's processing facility tested positive for the strain of salmonella similar to those related to the persons sickened in the outbreak, the CDC said. August Egg Co. said its internal food safety team is conducting its own investigation to "identify what measures can be established to prevent this situation from recurring," the company said in a statement accompanying the recall. 'It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." USA TODAY Recall Database: Search vehicle, product and food recalls The recalled eggs were distributed beginning Feb. 3 across multiple retailers in nine states: Eggs with sell-by dates to June 4: Through May 15, eggs with those sell-by dates were distributed to Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less and Ralphs stores in California and Nevada. Eggs with sell-by dates to June 19: Through May 6, eggs with those sell-by dates were distributed to Walmart locations in California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana and Illinois. August Egg Co. said consumers can identify the recalled eggs by the plant code on one side of the egg carton. They can return the eggs to the place of purchase for a refund. Consumers with questions can call the company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT. Here's the products recalled with plant code and UPC. Salmonella causes about 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths each year in the U.S., according to the CDC and FDA. Symptoms of salmonella infection – including diarrhea, fever and stomach cramps – typically arise six hours to six days after exposure and may last 4 to 7 days. Severe infections can also include aches, headaches, elevated fever, lethargy, rashes, and blood in the urine or stool. Salmonella poisoning, also known as salmonellosis, is a common gastrointestinal infection in California, with about 5,000 confirmed cases annually, according to the California Department of Public Health. The Centers for Disease Control estimates that around 3,000 people die from a foodborne illness, and of those about 420 people die from Salmonella infections. This article originally appeared on Palm Springs Desert Sun: Egg recall 2025: Salmonella risk for eggs sold at California stores
Epoch Times
3 hours ago
- Epoch Times
Nasal, Baby Teething Swabs Recalled Nationwide Over Microbial Contamination Fears
New Jersey-based Church & Dwight Co., Inc. is recalling three nasal and baby teething swab products due to potential fungal contamination in the cotton swab components, the company said in a June 6 The recall is applicable to three products: Zicam Cold Remedy Nasal Swabs designed to tackle the common cold, Zicam Nasal AllClear Swabs used for cleansing, and Orajel Baby Teething Swabs aimed at soothing teething discomfort among toddlers and infants.
